A new natural painkiller based on a body-own molecule, available as supplement. An educational video on its mechanism of action: palmitoylethanolamide (PEA) is a new compound ready 4 use in the clinic to calm glia and mast cells in all states of chronic pain. Thus it focusses on 2 new targets in the treatment of pain: these extra-neuronal targets in chronic pain can be modulated by PEA.

Recent studies show that administration of PEA in glaucoma patients has a double effect, decrease the IOP and neuroprotection. The IOP is the major risk factor in glaucoma, constricts blood vessels and reduces the delivery of oxygen and nutrients to the retina and optic nerve (ON), causing a process of ischemia and cell death (apoptosis).
New research points out palmitoylethanolamide has a dual action in glaucoma:

1. It reduces high eye pressure by promoting fluid flow out of the eye, and

2. PEA protects nerve cells and retina cells via its neuroprotective and reparative properties.

In the Youtube the essence of the natural treatment of glaucoma with palmitoylethanolamide has been summarized. Daily dose: 2-3 times 400 mg palmitoylethanolamide. Literature on this topic on http://palmitoylethanolamide4pain.com/2015/02/20/youtube-on-palmitoylethanolamide-as-a-natural-treatment-for-glaucoma/

Neuropathic pain: often difficult to treat. Palmitoylethanolamide (PEA) is a very special molecule, produced in our own body, against pain and chronic inflammation. PEA is available as supplement and as cream, and as dietfood for medical purposes in Italy and Spain. It has been explored since 1957 and has a clear analgesic and anti-inflammatory efficacy, and virtually no side effects. Meanwhile within the context of clinical trials 5000 patients have been using PEA, and its efficacy and safety has been documented in more than 400 scientific papers: http://palmitoylethanolamide4pain.com/about-2/ a website containing 400+ scientific articles on PEA in 6 different languages. The PEA datapool.

La palmitoiletanolamide (PeaVera, PeaPure, Palmidrol, Achille e altri PEA prodotti rappresenta una rivoluzione nel trattamento del dolore. Si tratta di un efficace analgesico naturale, senza effetti collaterali. La sua azione è stata documentata in molte centinaia di articoli scientifici. Il suo meccanismo è stato scoperto dalla professoressa Rita Levi Montalcini, premio Nobel per la medicina.

Qui è disponibile una breve introduzione su questa sostanza particolare. (Qui Informazioni per i medici) PEA è disponibile in Italia dal 2007 ed è stata classificata dal Ministero della Salute italiano come alimento dietetico per fini medici speciali.

Ruth’s testimonial on her amazing experience with cosmetic dental procedures offered by Dr Jamil Alkhoury at Brentwood Family Dental

Video of brain surgery

Acne, or acne vulgaris, is a skin problem that starts when oil and dead skin cells clog up your pores. Some people call it blackheads, blemishes, whiteheads, pimples, or zits. Check out the video for detailed research study on Acne vulgaris and provide us feedbacks. Please subscribe for regular updates...............

http://www.thenyac.com/ Like Restylane and Juvederm, Belotero Balance is an FDA approved component for the correction of moderate-to-severe facial wrinkles, superficial lines, folds and upper lip. A doctor can use both Juvederm and Restylane on deeper areas and Belotero on top to correct wrinkles, lines and folds. In addition acne scars can benefit from fillers like Belotero

http://www.drmarylupo.com/ Rosacea is sometimes called 'adult acne', but it's not. Over 14million Americans have Rosacea. For most, Rosacea is an embarrassing cyclical condition, coming and going.

Ultherapy was designed by Ulthera to deliver intense focused ultrasound energy deep to the dermal tissues under the epidermis, without injury to the surface of the skin, to lift and tighten facial tissues. It has been used to tighten off-the-face areas too, without surgery and without down time. In just about one hour an entire face can be treated. Medication makes the procedure less uncomfortable.

Dr. Lupo speaks on dermal fillers and which filler to use in which situation. Start by calling Dr. Mary Lupo at (504) 288-2381, or visit her website www.drmarylupo.com for more info!

Dermatologist in New Orleans, Dr. Lupo, talks in a television interviews about Dermatology.

Chronic myelogenous leukemia (CML), also known as chronic myeloid leukemia, is a myeloproliferative disorder characterized by increased proliferation of the granulocytic cell line without the loss of their capacity to differentiate. Consequently, the peripheral blood cell profile shows an increased number of granulocytes and their immature precursors, including occasional blast cells.

CML is one of the few cancers known to be caused by a single, specific genetic mutation. More than 90% of cases result from a cytogenetic aberration known as the Philadelphia chromosome (see Pathophysiology).

CML progresses through 3 phases: chronic, accelerated, and blast. In the chronic phase of disease, mature cells proliferate; in the accelerated phase, additional cytogenetic abnormalities occur; in the blast phase, immature cells rapidly proliferate.[1] Approximately 85% of patients are diagnosed in the chronic phase and then progress to the accelerated and blast phases after 3-5 years. The diagnosis of CML is based on the histopathologic findings in the peripheral blood and the Philadelphia chromosome in bone marrow cells (see Workup).

CML accounts for 20% of all leukemias affecting adults. It typically affects middle-aged individuals. Uncommonly, the disease occurs in younger individuals. Younger patients may present with a more aggressive form of CML, such as in accelerated phase or blast crisis. Uncommonly, CML may appear as a disease of new onset in elderly individuals.

The goals of treatment are to achieve hematologic, cytogenetic, and molecular remission. Although a variety of medications have been used in CML, including myelosuppressive agents and interferon alfa, the tyrosine kinase inhibitor imatinib mesylate is currently the agent of choice, and other drugs in this category are playing increasingly important roles. However, allogeneic bone marrow transplantation is currently the only proven cure for CML.

http://www.landging.com/car-crash-animations-front.html Car crash animations, accident reconstruction, front end collision.

http://www.landging.com/nervous-system-animation.html Human body nervous system, 3D MOA (Mechanism of Action) animation, designed for Beijing Natural History Museum.

http://www.landging.com/dental-animation.html 3D teeth virtual reality animation with high quality textures, for patient education purpose.

http://www.landging.com Customize your medical animation | Wow your clients with 3D animation | Outsource to China and reduce risk with a trial project.

Austin Vampire Facelift provider Dr. David Sneed gives us a comprehensive overview of this new facial rejuvenation technology also known as PRP. This nonsurgical anti-aging treatment utilizes the patient's own blood to stimulate the growth of new collagen, tighten skin and smooth out wrinkles.

M.Torabi Nami MD, PhDc Department of Neuroscience Institute for Cognitive Science Studies (ICSS), Tehran 15948 Iran Torabi_m@iricss.org Abstract Sleepiness, tiredness and fatigue are complaints which must be thoroughly analyzed to eliminate blur and ambiguity. Physiological sleepiness (“sleep pressure”) increases while being awake and additionally underlies the circadian rhythm with a lower threshold to fall asleep during night time. Excessive daytime sleepiness (EDS) is considered normal only after sleep deprivation. Clinically, EDS manifests by frequents daytime napping and/or reduced alertness with automatic behavior or - in its extreme form - in recurrent attacks of sudden, uncontrollable compulsion to sleep also in inappropriate situations (= “sleep attacks”). EDS is “objectively” addressed by measuring the mean sleep latency to four to five nap opportunities throughout the day using the multiple sleep latency test (MSLT) or the maintenance of wakefulness test (MWT). EDS denotes both, a ready entrance into sleep as well as difficulty in staying awake during daytime or accordingly in inappropriate situations. These two partially independent aspects of EDS are separately assessed by the “passive” MSLT and the “active” MWT respectively. For that reason the MSLT and MWT only weakly correlate with each other when tested over a broad range of patients with EDS. It is important to keep in mind, that these tests are importantly influenced by a great variety of factors such as mood, anxiety, and motivation. “Vigilance” comprises wakefulness, alertness and attention and therefore is more than just the reciprocal to sleepiness. Cognitive performance tasks such as Steer Clear Reaction Time Test (SCRTT) or driving simulators require the complete integrity of vigilance to achieve normal results. Hypersomnia is usually broadly defined as the combination of abnormally prolonged night-time sleep (regularly >10 h) with EDS during ≥1 months. On the other hand, the term hypersomnia has also been used in a narrower scene for the isolated abnormality of a prolonged night-time sleep need (>10 h). “Tiredness”, also in colloquial language often used for sleepiness, in a broader sense also describes the feeling of lack of energy, motivation and initiative. These patients seek rest rather than sleep. They often cannot fall asleep when given the opportunity in spite of feeling tired, and hence, in an MSLT, do not show an abnormally short sleep latency. Furthermore, tiredness (and fatigue) as opposed to sleepiness has a mental (“central”) and physiological (bodily or “peripheral”) component, which the patients can readily distinguish. Patients with insomnia, mild sleep apnea syndrome, or depression rather suffer from mental tiredness than sleepiness during the day. The simple subjective self-assessment using the Epworth Sleepiness Scale (ESS) quite reliably differentiates between sleepiness and mental tiredness (without sleepiness), which makes it a widely used test. The term “fatigue” is also heterogeneously used. In physiology the “fatigue” implied a “time on task performance decrement” to describe decreasing muscle force during a sustained physical effort. In clinical medicine one distinguishes physical (“peripheral”) from mental (“central”) fatigue and the term usually denotes a chronic and more abnormal situation than tiredness. In a broad sense “fatigue” implies a deficiency in coping satisfactorily with mental and physical work load. The chronic fatigue syndrome entails both mental as well as a physical fatigue (so called “leaden paralysis” of limbs). Depressive states are often associated with insomnia and fatigue, but there are also cases with hypersomnia rather than insomnia ( non organic hypersomnia , “atypical depression” or “hypersom

Brain Concussion in Sports